Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing innovative medicines for patients with serious diseases. Its core products include treatments for sleep disorders, epilepsy, and oncology. Major business segments encompass neuroscience and oncology, with primary revenue sources derived from product sales in these therapeutic areas.
The investment profile of Jazz Pharmaceuticals is more aligned with balanced investors, given its focus on both growth through innovative product development and stability in established therapeutic areas. The stock may appeal to those seeking moderate risk and potential for capital appreciation without significant volatility.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-11-08 | Hold | Buy | Strong revenue growth, but mixed analyst signals present risks. |
| 2026-11-06 | Buy | Hold | Mixed performance; high risk with uncertain momentum. |
| 2026-11-04 | Sell | Buy | Positive momentum but recent EPS surprise raises concerns. |
| 2026-10-09 | Hold | Sell | Weak momentum and high risk; cautious approach advised. |
| 2026-09-24 | Buy | Hold | Weak momentum and high risk; cautious approach advised. |
| 2026-09-22 | Hold | Buy | Solid fundamentals, but mixed momentum signals present uncertainty. |
| 2026-09-11 | Buy | Hold | Mixed performance; cautious outlook amid market volatility. |
| 2026-09-04 | Hold | Buy | Strong performance, but mixed analyst signals create uncertainty. |
| 2026-08-27 | Buy | Hold | Mixed performance; high risk with uncertain momentum. |
| 2026-08-20 | Hold | Buy | Solid growth, but recent EPS surprise raises concerns. |
| 2026-08-12 | — | Hold | Weak momentum and high risk offset potential upside. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-11-09 | Bernstein | Target Lowered | — → 220 | 240.1096 |
| 2026-10-21 | Morgan Stanley | Target Lowered | 322 → 314 | 213.34 |
| 2026-10-08 | RBC Capital | Target Lowered | 299 → 296 | 219.06 |
| 2026-10-07 | Truist Financial | Target Raised | 281 → 286 | 233.495 |
| 2026-09-24 | Goldman Sachs | Update | — → 337 | 234.88 |
| 2026-09-11 | UBS | Target Raised | 315 → 337 | 245.35 |
| 2026-09-10 | Barclays | Target Raised | 270 → 271 | 241.31 |
| 2026-08-28 | RBC Capital | Target Raised | 277 → 299 | 247.45 |
| 2026-08-26 | RBC Capital | Target Raised | — → 277 | 257.5371 |
| 2026-08-26 | Truist Financial | Target Raised | 264 → 281 | 257.04 |
| 2026-08-26 | Morgan Stanley | Target Raised | 283 → 322 | 257.518 |
| 2026-08-26 | Needham | Target Raised | 292 → 310 | 260.23 |
| 2026-08-26 | Canaccord Genuity | Update | — → 300 | 260.23 |
| 2026-08-26 | Deutsche Bank | Target Raised | — → 300 | 260.23 |
| 2026-08-11 | Morgan Stanley | Target Raised | 280 → 283 | 252.195 |
| 2026-08-04 | Deutsche Bank | Target Raised | 270 → 287 | 252.56 |
| 2026-08-04 | Truist Financial | Target Raised | — → 300 | 250.22 |
| 2026-08-04 | Morgan Stanley | Target Raised | 245 → 280 | 255.414 |
| 2026-08-04 | Truist Financial | Target Raised | 254 → 264 | 251.58 |
| 2026-08-04 | Needham | Target Raised | — → 292 | 251.58 |
| 2026-08-04 | UBS | Target Raised | 307 → 315 | 251.58 |
| 2026-08-04 | Wells Fargo | Target Raised | 285 → 300 | 251.58 |
| 2026-08-04 | Stifel Nicolaus | Target Raised | 230 → 275 | 251.58 |
| 2026-08-04 | Piper Sandler | Target Raised | 301 → 310 | 251.58 |
